BCDA

BioCardia, Inc.

3.56 USD
+0.56 (+18.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioCardia, Inc. stock is down -27.49% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 27 June’s closed higher than May. 100% of analysts rate it a buy.

About BioCardia, Inc.

BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.